Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer

Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study

NCT04517526 ·Status: UNKNOWN ·Phase: PHASE2

A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection

NCT05514314 ·Status: UNKNOWN ·Phase: PHASE2

A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC

NCT06422546 ·Status: RECRUITING

Evaluate EGFR Mutation Status and Impact Factors in North China

NCT02620657 ·Status: COMPLETED

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

NCT03866499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1

NCT04718012 ·Status: COMPLETED

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

NCT04811001 ·Status: UNKNOWN ·Phase: PHASE2

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

NCT03567642 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

NCT06281964 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

NCT03175224 ·Status: RECRUITING ·Phase: PHASE2

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

NCT04144569 ·Status: RECRUITING ·Phase: PHASE2

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT00536107 ·Status: TERMINATED ·Phase: PHASE4

Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)

NCT00154739 ·Status: COMPLETED ·Phase: PHASE2

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

NCT03381066 ·Status: UNKNOWN ·Phase: PHASE3

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164 ·Status: RECRUITING

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

NCT05997719 ·Status: RECRUITING

A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer

NCT01874678 ·Status: COMPLETED ·Phase: NA

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT06538038 ·Status: RECRUITING

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

NCT05055999 ·Status: COMPLETED

Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma

NCT06918782 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer

NCT01797913 ·Status: COMPLETED ·Phase: PHASE2

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

NCT05209256 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

GILT Docetaxel - Non-Small Cell Lung Cancer

NCT00174629 ·Status: COMPLETED ·Phase: PHASE3

PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT06590194 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951 ·Status: TERMINATED ·Phase: PHASE2